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Hidesaku AsakuraAbstract
Disseminated intravascular coagulation (DIC) has a common pathogenesis in terms of persistent widespread
activation of coagulation in the presence of underlying disease, but the degree of fibrinolytic activation often differs
by DIC type. DIC with suppressed fibrinolysis is a DIC type usually seen in sepsis. Coagulation activation is severe,
but fibrinolytic activation is mild. DIC with enhanced fibrinolysis is a DIC type usually seen in acute promyelocytic
leukemia (APL). Both coagulation activation and fibrinolytic activation are severe. DIC with balanced fibrinolysis is a
DIC type usually seen in solid tumors, with an intermediate pathogenesis between the above two types. In animal
DIC models, lipopolysaccharide (LPS)-induced models are similar to suppressed-fibrinolytic-type DIC, whereas tissue
factor (TF)-induced models are similar to enhanced fibrinolytic/balanced fibrinolytic DIC. Appropriate diagnosis and
treatment may also differ depending on the DIC type.
Keywords: Disseminated intravascular coagulation, DIC with suppressed fibrinolysis, DIC with enhanced fibrinolysis,
DIC with balanced fibrinolysis, Tranexamic acidIntroduction
Disseminated intravascular coagulation (DIC) is a serious
condition in which there is widespread and persistent acti-
vation of coagulation in the presence of underlying disease
that causes diffuse microthrombi in small blood vessels. In
addition to coagulation activation, fibrinolytic activation
occurs, but the degree of fibrinolysis varies considerably
depending on the underlying disease. With DIC progres-
sion, hemostatic factors such as platelets and clotting
factors are depleted, thus leading to consumption coagu-
lopathy [1-4].
The two major types of symptoms in DIC are bleeding
symptoms and organ symptoms, and when clinical
symptoms develop, the prognosis is usually poor. There-
fore, treatment should ideally be started before the onset
of clinical symptoms.
The Scientific Standards Committee (SSC) of the Inter-
national Society on Thrombosis and Hemostasis (ISTH)
defines DIC as ‘an acquired syndrome characterized by
the intravascular activation of coagulation with loss of
localization arising from different causes. It can originate
from and cause damage to the microvasculature, which ifCorrespondence: hasakura@staff.kanazawa-u.ac.jp
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unless otherwise stated.sufficiently severe, can produce organ dysfunction’ [5].
This statement by the ISTH currently represents a gener-
ally accepted international definition of DIC. It certainly
applies to the pathogenesis of DIC seen in severe infec-
tions such as sepsis. However, problems exist with this
definition in terms of not taking into account the type of
DIC often seen in acute leukemias (especially acute pro-
myelocytic leukemia (APL)), aortic aneurysm, abruptio
placentae, and metastatic prostate cancer; namely, DIC in
which severe bleeding symptoms are common due to en-
hanced fibrinolytic activity, but with very few organ symp-
toms [6,7].Review
Diversity of DIC states
The three most common clinical conditions associated
with DIC are sepsis, acute leukemia, and solid cancers,
but many other underlying conditions may also be asso-
ciated with DIC, including a variety of severe infections,
trauma, burns, heat stroke, surgery, abdominal aortic
aneurysm, giant hemangioma, connective tissue disease
(particularly vasculitis), obstetric complications (abruptio
placentae, amniotic embolism), fulminant hepatitis,
acute pancreatitis, shock, and rhabdomyolysis.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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vere infections such as sepsis. In sepsis, the actions of
inflammatory cytokines such as tumor necrosis factor
(TNF) and interleukin-1 (IL-1) cause production of large
amounts of tissue factor (TF) from monocytes/macro-
phages and the vascular endothelium, thus leading to
marked coagulation activation. In addition, lipopolysac-
charide (LPS) and cytokines inhibit the expression of
thrombomodulin (TM), an anti-clotting protein in the
vascular endothelium, thus increasing coagulation acti-
vation. Fibrinolysis is also activated in an attempt to dis-
solve some of the multiple microthrombi that occur as a
result of coagulation activation, but plasminogen activa-
tor inhibitor (PAI) is overexpressed in the vascular endo-
thelium due to the action of LPS and cytokines, and the
fibrinolysis is suppressed. Therefore, many microthrombi
remain, and the microcirculatory dysfunction leads to
progression of multiorgan failure [1,4].
On the other hand, in malignant tumors such as acute
leukemias and solid cancers, activation of extrinsic co-
agulation by TF in tumor cells is thought to cause DIC.
This is more direct coagulation activation from the stand-
point of almost no involvement of the vascular endothe-
lium or inflammation [8].
Crosstalk between inflammation and coagulation
Several recent reports have described the presence
of crosstalk between inflammation and coagulation
[9-12]. Namely, coagulation is activated by inflammation
(LPS, cytokines), and the generated thrombin andFigure 1 Classification of DIC types. Coagulation activation (TAT elevatio
elevation) differs depending on the underlying disease. The ‘symptoms’ are
Fibrin degradation product (FDP) is not shown in this figure, but in enhanc
Because ATRA therapy in APL inhibits annexin II expression in APL cells, the
to the characteristics of suppressed fibrinolytic DIC. TAT thrombin-antithrom
PAI plasminogen activator inhibitor, APL acute promyelocytic leukemia.activated factor X cause inflammation via protease-
activated receptors (PARs). In a study by our group
using an LPS-induced DIC model (sepsis DIC model),
the administration of immunoglobulin inhibited the in-
flammatory cytokines TNF and interleukin-6 (IL-6), and
coagulation and pathological thrombus formation were
suppressed [13]. Further development of this type of
treatment to block crosstalk between inflammation and
coagulation is expected in the future.
However, although this phenomenon may exist in
infections (sepsis and LPS-induced DIC models), its
presence in non-infectious cases (acute leukemia, solid
cancers, and TF-induced DIC models) is doubtful (or if
present, it is fairly limited) [14].
The involvement of cytokines and vascular endothe-
lium and the presence of crosstalk between coagulation
and inflammation in DIC pathogenesis, even if applic-
able to infectious cases (LPS-induced DIC model), is not
universally applicable to all cases of DIC.
Classification of clinical DIC types
The concept of DIC type classification is important in
understanding the diversity of DIC (Figure 1). Marked
activation of coagulation is a major pathogenetic factor
in DIC and is common to all DIC types, but other as-
pects of the pathogenesis (especially the degree of
fibrinolytic activation) differ considerably depending on
the underlying disease. PAI regulates the degree of
fibrinolytic activation and is an important factor in char-
acterizing DIC (Figure 2).n) is a common feature, but the degree of fibrinolytic activation (PIC
a in the figure distinguishes organ symptoms and bleeding symptoms.
ed fibrinolytic DIC, FDP tends to be elevated more than D-dimer.
characteristics of enhanced fibrinolytic DIC are lost, with a change
bin complex, PIC plasmin-α2 plasmin complex, DD D-dimer,
Figure 2 Role of fibrinolysis in DIC. The dotted-line arrows summarize the reaction steps. Even with extensive thrombus, when fibrinolysis is
inhibited by the action of PAI, plasmin formation is low, so the thrombi do not easily dissolve, and FDP and D-dimer elevations are mild (for
example, DIC in sepsis). On the other hand, when PAI activity is low, plasmin formation increases, the thrombi dissolve more easily, and there
are higher elevations of FDP and D-dimer (for example, DIC in APL). FDP and D-dimer are important markers for DIC, but their degree of elevation
may not correlate with DIC severity (in particular, the degree of organ dysfunction). t-PA tissue type plasminogen activator, PAI plasminogen
activator inhibitor, TF tissue factor, VIIa activated factor VII.
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fibrinolysis)
Suppressed-fibrinolytic-type DIC, in which coagulation
activation is severe but fibrinolytic activation is mild, is
typically seen in sepsis. Because the fibrinolytic inhibi-
tory factor PAI is markedly increased, fibrinolysis is
strongly suppressed, the dissolution of multiple micro-
thrombi is more difficult, and as a result of microcircula-
tory impairment, severe organ dysfunction may occur.
However, bleeding complications are relatively mild.
Laboratory findings include an elevation in thrombin-
antithrombin complex (TAT), a coagulation activation
marker, but plasmin-α2 plasmin inhibitor complex (PIC),
a fibrinolysis activation marker, is only mildly elevated
(Figures 3 and 4) [6,15-17]. This type of DIC is called
‘suppressed-fibrinolytic-type DIC.’ In addition, fibrin/fi-
brinogen degradation products (FDPs) and D-dimer,
which reflect dissolution of microthrombi, are also only
relatively mildly increased. Furthermore, α2 plasmin in-
hibitor (α2PI) is a protein normally consumed and depleted
in DIC, but in suppressed-fibrinolytic-type DIC, plasmin
production is low, and α2PI is increased by inflammation.
Therefore, α2PI levels are almost normal or only slightly
decreased in DIC with fibrinolysis suppression.
Enhanced-fibrinolytic-type DIC (DIC with enhanced
fibrinolysis)
On the other hand, enhanced-fibrinolytic-type DIC, in
which DIC is associated with marked fibrinolysis activa-
tion corresponding to coagulation activation, is typicallyseen in APL, abdominal aortic aneurysm, and prostate
cancer. Fibrinolysis is strongly activated, with hardly any
elevation in PAI; hemostatic plugs (thrombi due to
hemostasis) are more easily dissolved; and bleeding
symptoms tend to be severe. However, organ dysfunc-
tion seldom occurs.
Laboratory findings show a marked elevation in both
TAT and PIC, and FDPs and D-dimer are also elevated
(Figures 3 and 4) [6,15-17]. This type of DIC is called ‘en-
hanced-fibrinolytic-type DIC.’ Because fibrinogen degener-
ation progresses, the FDP/D-dimer ratio tends to increase
(decrease when expressed as the D-dimer/FDP ratio).
Balanced-fibrinolytic-type DIC (DIC with balanced
fibrinolysis)
DIC with a balance between coagulation activation and
fibrinolytic activation, with an intermediate pathogenesis
between the above-mentioned types, is called ‘balanced-
fibrinolytic-type DIC.’ Bleeding symptoms and organ
symptoms are relatively uncommon except in advanced
cases. This type of DIC is common in solid cancers, but
it may progress to DIC with enhanced fibrinolysis in
some cancers, such as prostate cancer and vascular
malignancies.
Classifying DIC types based on differences in patho-
genesis is important to make an early diagnosis of DIC
and plan treatment. For example, FDP and D-dimer have
been regarded as the most important markers to diag-
nose DIC, but in suppressed-fibrinolytic-type DIC, these
markers are often only mildly elevated. If an over-
Figure 3 Changes in plasma TAT and PIC in DIC. The horizontal
lines show the upper limits of normal. Plasma TAT is elevated in all
cases of DIC. However, the degree of plasma PIC elevation differs
depending on the underlying disease. The increase in PIC is highest
in APL and lowest in sepsis. TAT thrombin-antithrombin complex, PIC
plasmin-α2 plasmin complex, APL acute promyelocytic leukemia, AL
acute leukemia except APL, Ca cancer, Sep sepsis.
Figure 4 Variations in active PAI in DIC. The horizontal line shows
the upper limits of normal. Plasma active PAI shows the highest
elevation in sepsis but is within normal limits in APL. PAI
plasminogen activator inhibitor, APL acute promyelocytic leukemia,
AL acute leukemia except APL, Ca cancer, Sep sepsis.
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DIC may be delayed. By focusing on increases in plasma
TAT and soluble fibrin (SF) and serial decreases in plate-
let counts, DIC can be diagnosed earlier. From a treat-
ment perspective, administration of heparin drugs alone
can further promote bleeding in enhanced-fibrinolytic-
type DIC. In these cases, administration of nafamostat
mesilate (an antithrombin drug with potent antiplasmin
activity) or a combination of heparin and tranexamic
acid may be effective [18-22]. These drugs are also useful
for saving fresh frozen plasma and platelet concentrates
in enhanced-fibrinolytic-type DIC.
Gando et al. called the DIC seen in trauma with early
severe activation of fibrinolytic activity ‘DIC with a fi-
brinolytic phenotype,’ but they reported that 24–48 h
after trauma, this changed to a ‘thrombotic phenotype’
due to the action of PAI [23,24]. In DIC due to trauma,
tranexamic acid should only be administered during the
period of DIC with the fibrinolytic phenotype. DIC
with the fibrinolytic phenotype is a concept close to
enhanced-fibrinolytic-type DIC, whereas DIC with the
thrombotic phenotype is a concept close to suppressed-
fibrinolytic-type DIC.
Classification of animal DIC model types
For animal DIC models, conventional LPS-induced
models and TF-induced models (particularly the former)
are frequently used and, in fact, they are often regarded
as similar models without being differentiated. However,
the authors have found that even when the degree of co-
agulation activation as reflected by increased plasma
TAT, or the degree of consumption coagulopathy as
reflected by decreased platelet counts and fibrinogen, is
similar, the pathogenesis differs greatly depending on the
DIC-inducing substance that is used [25].
In the ‘LPS-induced DIC model,’ fibrinolysis is sup-
pressed due to markedly increased PAI activity, and
D-dimer is only mildly elevated. Multiple microthrombi
are histopathologically easy to demonstrate. Organ dys-
function, including hepatorenal dysfunction, is severe,
but despite a marked decrease in platelet counts and
fibrinogen, bleeding symptoms are rarely seen [25].
In the ‘TF-induced DIC model,’ PAI activity is only
mildly elevated, and steep increases in D-dimer levels re-
flect adequate fibrinolytic activation. Microthrombi are
histopathologically difficult to demonstrate (thought to
reflect thrombolysis). Interestingly, although hepatorenal
dysfunction is seldom observed, hematuria commonly
occurs as a sign of bleeding [25]. In addition, because of
marked fibrinolytic activation, both fibrin degradation
and fibrinogen degradation progress [26].
In both DIC models, despite a similar degree of de-
crease in platelet counts and fibrinogen, the rate of
bleeding symptoms is high only in the TF-induced DIC
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are more closely related to fibrinolytic activation than to
the degree of consumption coagulopathy. Furthermore,
even though coagulation activation (plasma TAT eleva-
tion) is similar in both DIC models, organ dysfunction is
only seen in the LPS-induced DIC model. This suggests
that organ dysfunction in DIC is more closely related to
the degree of fibrinolytic activation than to the coagula-
tion activation.
Therefore, the LPS-induced DIC model is clinically
similar in pathogenesis to suppressed-fibrinolytic-type
DIC, whereas the TF-induced DIC model is similar to
enhanced-fibrinolytic-type or balanced-fibrinolytic-type
DIC. Research to analyze DIC pathogenesis and develop
novel therapies is being conducted using animal DIC
models. However, the results are likely to differ greatly
depending on the model used. This point is an import-
ant issue with regards to DIC research.
Significance of fibrinolytic activation in animal DIC
models
The fact that fibrinolytic activation plays an important
role in DIC models has been confirmed by evaluating
the effects of administering tranexamic acid (TA), an
antifibrinolytic drug, in both models [27,28]. In the
TF-induced DIC model, although hepatorenal dysfunc-
tion is seldom observed (hematuria occurs at a high
frequency), when TA is administered, severe organ dys-
function similar to that in the LPS model is observed
(the hematuria disappears). In the LPS-induced DIC
model, hepatorenal dysfunction is severe, and when TA
is administered, there is even further worsening of organ
dysfunction. Based on these findings, excessive fibrino-
lytic activation in DIC causes bleeding, but moderate
fibrinolytic activation has a preventive effect against
organ dysfunction as a biological defense response.
In the LPS-induced DIC model, a marked increase in
PAI suppresses fibrinolysis and causes worsening of
organ dysfunction. Fibrinolytic therapy in this model
may reduce organ dysfunction. In fact, in a study in
which the authors administered urokinase in an LPS
model, the increase in PAI activity was suppressed and
organ dysfunction was significantly improved [29]. Be-
cause problems such as adverse reactions must still be
resolved, these findings cannot be immediately applied
in clinical practice. Nevertheless, these are thought-
provoking results when considering the pathogenesis in
LPS-induced DIC models.
Diagnostic criteria for enhanced fibrinolytic DIC
In DIC with enhanced fibrinolysis, particularly with se-
vere bleeding symptoms that are clinically difficult to
control, antifibrinolytic therapy, which is normally
contraindicated in DIC, may indeed be indicated(in combination with heparin). However, criteria must
be clearly defined to avoid incorrect indications.
The bleeding symptoms in enhanced fibrinolytic DIC
are severe, and life-threatening bleeding, including cere-
bral hemorrhage, pulmonary hemorrhage, hematemesis/
melena, and massive bleeding from surgical and wound
sites, may occur. Although platelet depletion is usually
not severe in this type of DIC, caution is necessary be-
cause life-threatening bleeding may still occur.
When enhanced fibrinolytic DIC is treated with hep-
arin alone, the bleeding may actually increase, but treat-
ment to adequately inhibit both coagulation activation
and fibrinolytic activation is often very effective for
bleeding symptoms. Specifically, combination therapy
with nafamostat mesilate or heparin and tranexamic acid
may be very effective for bleeding symptoms in DIC
with enhanced fibrinolysis [18-22]. However, with antifi-
brinolytic therapy in DIC, complications such as life-
threatening thrombosis and organ failure have been
reported, and incorrect indications and use of drugs can
lead to serious complications [30-32].
Differential induction therapy with all-trans retinoic
acid (ATRA) in APL decreases annexin II expression,
and the characteristics of enhanced fibrinolytic DIC
change to those of suppressed fibrinolytic DIC [33].
Tranexamic acid is contraindicated when using ATRA.
In fact, life-threatening systemic thrombosis has been re-
ported with antifibrinolytic therapy when using ATRA in
APL [34-36].
The diagnostic criteria for enhanced fibrinolytic DIC are
also important to avoid incorrect indications for antifibrino-
lytic therapy. The following lists the criteria for diagnosing
DIC with enhanced fibrinolysis (enhanced-fibrinolytic-type
DIC):
1. Prerequisite: TAT ≥20 μg/L and PIC ≥10 μg/L
2. Laboratory findings - at least two of the following
findings:
(1) FDP ≥80 μg/mL
(2) Fibrinogen <100 mg/dL
(3) Increased FDP/D-dimer ratio (decreased
D-dimer/FDP ratio)
3. Reference findings - more severe bleeding is likely
with the following findings:
(1) Decreased platelet count (<50,000/μL)
(2) Decreased α2PI activity (<50%)
Many classic cases meet these prerequisite criteria.
Elevations of TAT and PIC to 70%–80% of the above
levels are still sometimes regarded as DIC with enhanced
fibrinolysis.
For bleeding symptoms in enhanced fibrinolytic DIC,
the dissolution of hemostatic plugs associated with
marked fibrinolytic activation is more of a factor than is
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be depleted, bleeding symptoms may become more se-
vere. With excessive plasmin formation, α2PI is often
markedly decreased.
Conclusions
Widespread and persistent activation of coagulation is a
common feature in all types of DIC, but there are also
many differences. The concept of classifying DIC types,
which recognizes the diversity of DIC, is important to
deepen our understanding of the DIC pathogenesis. In
addition, we are moving in the direction of more appro-
priate selection of treatment based on DIC type.
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